Who are efavirenz + emtricitabina + tenofovir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Switch to Triumeq, tenofovir, lamivudine, efavirenz, DOR/DTG/3TC, Eviplera®, Immediate switch to TDF/FTC/RPV, Tenofovir, lamivudine and efavirenz.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/efavirenz-emtricitabina-tenofovir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

efavirenz + emtricitabina + tenofovir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

efavirenz + emtricitabina + tenofovir (efavirenz + emtricitabina + tenofovir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NNRTI + NRTI + NtRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NNRTI + NRTI + NtRTI) HIV reverse transcriptase, HIV integrase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

efavirenz + emtricitabina + tenofovir (efavirenz + emtricitabina + tenofovir) — Hospital Universitari Vall d'Hebron Research Institute. This combination of three antiretroviral drugs suppresses HIV replication by inhibiting reverse transcriptase and blocking viral integration into host cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
efavirenz + emtricitabina + tenofovir TARGET	efavirenz + emtricitabina + tenofovir	Hospital Universitari Vall d'Hebron Research Institute	marketed	Antiretroviral combination therapy (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase
Switch to Triumeq	Switch to Triumeq	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Antiretroviral combination therapy (NRTI + INSTI)	HIV reverse transcriptase, HIV integrase
tenofovir, lamivudine, efavirenz	tenofovir, lamivudine, efavirenz	Bamrasnaradura Infectious Diseases Institute	marketed	Antiretroviral combination therapy (NRTI/NtRTI/NNRTI)	HIV reverse transcriptase, HIV integrase
DOR/DTG/3TC	DOR/DTG/3TC	Insel Gruppe AG, University Hospital Bern	marketed	Antiretroviral combination (NNRTI + INSTI + NRTI)	HIV reverse transcriptase, HIV integrase
Eviplera®	Eviplera®	St Stephens Aids Trust	marketed	Antiretroviral combination therapy (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase
Immediate switch to TDF/FTC/RPV	Immediate switch to TDF/FTC/RPV	Azienda Ospedaliera San Gerardo di Monza	marketed	Antiretroviral combination therapy (NRTI/NNRTI)	HIV reverse transcriptase, HIV integrase
Tenofovir, lamivudine and efavirenz	Tenofovir, lamivudine and efavirenz	Centre for the AIDS Programme of Research in South Africa	marketed	Antiretroviral combination therapy (NRTI/NtRTI + NNRTI)	HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NNRTI + NRTI + NtRTI) class)

Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
Prism Health North Texas · 1 drug in this class
St Stephens Aids Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). efavirenz + emtricitabina + tenofovir — Competitive Intelligence Brief. https://druglandscape.com/ci/efavirenz-emtricitabina-tenofovir. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab